Header Logo

Connection

Philip Bonomi to Adult

Back to Details
This is a "connection" page, showing publications Philip Bonomi has written about Adult.
Philip Bonomi
Connection Strength
0.838
Adult
  1. Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients. Ann Oncol. 2016 08; 27(8):1612-9.
    View in: PubMed
    Score: 0.057
  2. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2015 Mar 15; 121(6):883-92.
    View in: PubMed
    Score: 0.051
  3. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):338-45.
    View in: PubMed
    Score: 0.045
  4. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun; 6(6):1079-86.
    View in: PubMed
    Score: 0.040
  5. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol. 2009 Jul; 4(7):869-74.
    View in: PubMed
    Score: 0.035
  6. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul 10; 27(20):3284-9.
    View in: PubMed
    Score: 0.035
  7. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008 May 20; 98(10):1608-13.
    View in: PubMed
    Score: 0.033
  8. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol. 2007 Sep 01; 25(25):3936-44.
    View in: PubMed
    Score: 0.031
  9. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006 Nov 20; 24(33):5253-8.
    View in: PubMed
    Score: 0.029
  10. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16):3238-47.
    View in: PubMed
    Score: 0.025
  11. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586). Am J Clin Oncol. 2000 Aug; 23(4):371-5.
    View in: PubMed
    Score: 0.019
  12. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 2020 01; 10(1):40-53.
    View in: PubMed
    Score: 0.018
  13. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019 02 01; 37(4):278-285.
    View in: PubMed
    Score: 0.017
  14. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clin Cancer Res. 2019 01 01; 25(1):64-72.
    View in: PubMed
    Score: 0.017
  15. The serum-based VeriStrat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018 03 20; 18(1):310.
    View in: PubMed
    Score: 0.016
  16. An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Lung Cancer. 2017 02; 104:126-130.
    View in: PubMed
    Score: 0.015
  17. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995 Jun; 12(3):199-220.
    View in: PubMed
    Score: 0.013
  18. Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale. Am J Hosp Palliat Care. 2016 May; 33(4):374-80.
    View in: PubMed
    Score: 0.013
  19. Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by?Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2015 May; 16(3):200-8.
    View in: PubMed
    Score: 0.013
  20. Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma. Ann Thorac Surg. 2014 Dec; 98(6):1968-75; discussion 1975.
    View in: PubMed
    Score: 0.013
  21. Radiation and simultaneous cisplatin in non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1993 Oct 20; 27(3):739-46.
    View in: PubMed
    Score: 0.012
  22. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 01; 19(11):3068-77.
    View in: PubMed
    Score: 0.011
  23. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012 Dec; 21(4):207-13.
    View in: PubMed
    Score: 0.011
  24. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. J Thorac Oncol. 2012 Oct; 7(10):1618-21.
    View in: PubMed
    Score: 0.011
  25. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg. 2011 Jul; 92(1):233-41; discussion 241-3.
    View in: PubMed
    Score: 0.010
  26. Prognostic importance of subdividing clinically staged IIIa and IIIb patients with non-small-cell lung cancer. J Clin Oncol. 1991 Feb; 9(2):357-9.
    View in: PubMed
    Score: 0.010
  27. Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. Int J Cancer. 2011 Jul 01; 129(1):133-42.
    View in: PubMed
    Score: 0.010
  28. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):985-91.
    View in: PubMed
    Score: 0.010
  29. A multi-analyte serum test for the detection of non-small cell lung cancer. Br J Cancer. 2010 Oct 12; 103(8):1221-8.
    View in: PubMed
    Score: 0.010
  30. A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989 Sep; 34(3):357-9.
    View in: PubMed
    Score: 0.009
  31. Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Ann Thorac Surg. 2009 Sep; 88(3):937-43; discussion 944.
    View in: PubMed
    Score: 0.009
  32. A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. Am J Clin Oncol. 2009 Jun; 32(3):269-73.
    View in: PubMed
    Score: 0.009
  33. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J Thorac Oncol. 2009 Mar; 4(3):338-47.
    View in: PubMed
    Score: 0.009
  34. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008 Nov 20; 26(33):5407-15.
    View in: PubMed
    Score: 0.008
  35. Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen. Semin Oncol. 1988 Apr; 15(2 Suppl 1):26-33.
    View in: PubMed
    Score: 0.008
  36. Phase I trial of cisplatin and razoxane (ICRF-159) (NSC #119875) in advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Pilot Study. Am J Clin Oncol. 1988 Feb; 11(1):1-2.
    View in: PubMed
    Score: 0.008
  37. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007 Oct 20; 25(30):4743-50.
    View in: PubMed
    Score: 0.008
  38. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol. 2007 Aug 10; 25(23):3448-55.
    View in: PubMed
    Score: 0.008
  39. Phase II trial of mitomycin, vindesine, and hexamethylmelamine in metastatic non-small cell bronchogenic carcinoma. Cancer Treat Rep. 1986 Dec; 70(12):1447-8.
    View in: PubMed
    Score: 0.007
  40. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol. 2006 Nov; 81(2):163-7.
    View in: PubMed
    Score: 0.007
  41. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial. Lung Cancer. 2006 Jul; 53(1):77-83.
    View in: PubMed
    Score: 0.007
  42. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985 Aug; 3(8):1079-85.
    View in: PubMed
    Score: 0.007
  43. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res. 1985 Feb; 45(2):863-71.
    View in: PubMed
    Score: 0.006
  44. MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer. 2004 May; 40(8):1193-8.
    View in: PubMed
    Score: 0.006
  45. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003 Apr 15; 21(8):1536-43.
    View in: PubMed
    Score: 0.006
  46. Phase II trial of AMSA in patients with advanced or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Cancer Treat Rep. 1983 Feb; 67(2):197-8.
    View in: PubMed
    Score: 0.006
  47. ZD0473 treatment in lung cancer: an overview of the clinical trial results. Eur J Cancer. 2002 Dec; 38 Suppl 8:S13-8.
    View in: PubMed
    Score: 0.006
  48. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002 Mar; 55(3):285-95.
    View in: PubMed
    Score: 0.005
  49. The role of positron emission tomography in selecting patients with metastatic cancer for adrenalectomy. Am Surg. 2000 May; 66(5):432-6; discussion 436-7.
    View in: PubMed
    Score: 0.005
  50. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol. 2000 Jan; 18(1):131-5.
    View in: PubMed
    Score: 0.005
  51. A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer. 1999 Sep; 25(3):199-206.
    View in: PubMed
    Score: 0.004
  52. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res. 1999 Apr; 5(4):767-74.
    View in: PubMed
    Score: 0.004
  53. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Cancer. 1998 Jan 15; 82(2):292-300.
    View in: PubMed
    Score: 0.004
  54. Retreatment of recurrent invasive thymoma with platinum, doxorubicin, and cyclophosphamide. Chest. 1996 Oct; 110(4):1115-7.
    View in: PubMed
    Score: 0.004
  55. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer. 1996 Jun 15; 77(12):2503-13.
    View in: PubMed
    Score: 0.004
  56. Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588). Invest New Drugs. 1995; 13(2):137-41.
    View in: PubMed
    Score: 0.003
  57. Combined modality treatment using BID radiation for locally advanced non-small cell lung carcinoma. Cancer. 1994 May 15; 73(10):2599-606.
    View in: PubMed
    Score: 0.003
  58. Combined modality therapy for locally advanced non-small cell lung carcinoma. Cancer. 1990 Dec 01; 66(11):2270-8.
    View in: PubMed
    Score: 0.002
  59. Treatment of 29 patients with bulky squamous cell carcinoma of the cervix with simultaneous cisplatin, 5-fluorouracil, and split-course hyperfractionated radiation therapy. Gynecol Oncol. 1990 Sep; 38(3):323-7.
    View in: PubMed
    Score: 0.002
  60. Preoperative radiation therapy in regionally localized stage III non-small cell lung carcinoma: long-term results and patterns of failure. Int J Radiat Oncol Biol Phys. 1990 Aug; 19(2):287-92.
    View in: PubMed
    Score: 0.002
  61. A pilot study of the Functional Living Index-Cancer (FLIC) Scale for the assessment of quality of life for metastatic lung cancer patients. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1988 Dec; 11(6):630-3.
    View in: PubMed
    Score: 0.002
  62. Neuroendocrine carcinomas of the colon and rectum: a clinicopathologic evaluation. Surgery. 1988 Dec; 104(6):1080-9.
    View in: PubMed
    Score: 0.002
  63. Preoperative combined modality therapy for stage III M0 non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1988 Jul; 15(1):189-95.
    View in: PubMed
    Score: 0.002
  64. Megestrol acetate as primary hormonal therapy for advanced breast cancer. Semin Oncol. 1988 Apr; 15(2 Suppl 1):34-7.
    View in: PubMed
    Score: 0.002
  65. Sequential hormone therapy for advanced breast cancer. Semin Oncol. 1988 Apr; 15(2 Suppl 1):38-43.
    View in: PubMed
    Score: 0.002
  66. Hormone receptor studies in axillary metastases from occult breast cancers. Cancer. 1987 Mar 15; 59(6):1170-2.
    View in: PubMed
    Score: 0.002
  67. Simultaneous cisplatin fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III, non-small cell lung cancer. Ann Thorac Surg. 1987 Jan; 43(1):87-91.
    View in: PubMed
    Score: 0.002
  68. Treatment of soft tissue sarcoma with fibroblast interferon (beta-interferon): an American Cancer Society/Illinois Cancer Council Study. Cancer Treat Rep. 1986 Feb; 70(2):293-4.
    View in: PubMed
    Score: 0.002
  69. Metastatic breast cancer: preliminary results with oral hormonal therapy. Semin Oncol. 1985 Dec; 12(4 Suppl 6):61-4.
    View in: PubMed
    Score: 0.002
  70. Qualitative analysis of Coomassie-blue-stained proteins from normal prostate, benign prostatic hypertrophy, or adenocarcinoma of the prostate, separated by two-dimensional protein electrophoresis. Prostate. 1985; 6(3):315-23.
    View in: PubMed
    Score: 0.002
  71. A ten year experience with hepatic resection. Surg Gynecol Obstet. 1984 Sep; 159(3):223-8.
    View in: PubMed
    Score: 0.002
  72. Doxorubicin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer Treat Rep. 1984 Sep; 68(9):1163-5.
    View in: PubMed
    Score: 0.002
  73. Vindesine: phase II evaluation in colon cancer and description of its platelet stimulating activity. Cancer Chemother Pharmacol. 1982; 9(1):41-4.
    View in: PubMed
    Score: 0.001
  74. Neuroendocrine carcinoma of the cervix: implications for staging and therapy. Gynecol Oncol. 1981 Aug; 12(1):120-8.
    View in: PubMed
    Score: 0.001
  75. Response to megestrol in male breast carcinoma. Arch Intern Med. 1981 May; 141(6):809-10.
    View in: PubMed
    Score: 0.001
  76. Comparison of dextran-coated charcoal and sucrose density gradient analyses of estrogen and progesterone receptors in human breast cancer. Cancer Res. 1980 Nov; 40(11):4127-32.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.